Benzinga | Dec 17, 2020 06:41AM EST

H.C. Wainwright Initiates Coverage On Arbutus Biopharma with Buy Rating, Announces Price Target of $10

H.C. Wainwright analyst Ed Arce initiates coverage on Arbutus Biopharma (NASDAQ:ABUS) with a Buy rating and announces Price Target of $10.